Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac-GSK coronavirus variant vaccine generates good immune response in rats

05/17/2021 | 03:59am EDT
FILE PHOTO: Dose of CureVac vaccine or a placebo is seen in Brussels

LONDON (Reuters) - A second-generation COVID-19 vaccine developed by CureVac and GlaxoSmithKline, designed to protect against coronavirus variants, produced a high level of immune response in a trial in rats, the companies said on Thursday.

CureVac in February said it would team up with GlaxoSmithKline on a COVID-19 vaccine aimed at targeting several variants with one shot.

The shot uses messenger RNA technology, similar to successful vaccines made by Pfizer-BioNTech and Moderna, and clinical trials of the shot in humans are expected to start in the third quarter of this year.

The mRNA "backbone" of the shot differs from CureVac's first COVID-19 vaccine candidate, and it is designed to work well at lower doses.

Rats immunised with the shot, called CV2CoV, showed quick, strong immune responses, the companies said, and blood serum "showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), the UK (B.1.1.7) and South Africa (B.1.351)."

"To successfully fight the COVID-19 pandemic in the long term, we will need different vaccines and we need to be able to respond effectively to emerging variants," GSK Global Vaccines President Roger Connor said.

"We are pleased with these pre-clinical results as they show the potential of the next generation mRNA technology we are developing together with CureVac."

Although human trials are yet to start, these results mark a boost for GSK, the world's largest vaccine maker by sales.

GSK's collaboration with CureVac is a fresh attempt to play a major role in fighting the pandemic after a COVID-19 shot with Sanofi ran into delays and a collaboration with China's Clover Biopharmaceuticals was ended.

GSK, which acquired a 10% stake in CureVac last year, will also support the production of up to 100 million doses of CureVac's first-generation COVID-19 vaccine candidate.

CureVac's first generation COVID-19 vaccine is already in late-stage clinical trials.

(Reporting by Alistair Smout; Editing by Susan Fenton)

By Alistair Smout

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.75% 227.79 Delayed Quote.181.53%
CUREVAC N.V. 5.01% 59.76 Delayed Quote.-29.80%
DOW JONES AFRICA TITANS 50 INDEX 0.43% 530.1 Delayed Quote.-0.26%
DOW JONES SOUTH AFRICA(ZAR) 0.00% 1895.08 Delayed Quote.6.93%
GLAXOSMITHKLINE PLC -0.24% 1405.8 Delayed Quote.5.14%
MODERNA, INC. 3.82% 220.14 Delayed Quote.102.97%
PFIZER, INC. 0.36% 39.19 Delayed Quote.6.09%
S&P AFRICA 40 INDEX 0.00% 171.18 Delayed Quote.-1.34%
SANOFI 0.55% 87.6 Real-time Quote.11.31%
06/24VIFOR PHARMA  : Appoints Former GlaxoSmithKline Executive as CEO; Shares Down 5%
06/24Roche's Actemra gets U.S. FDA approval for hospitalized COVID-19 patients
06/24Today on Wall Street: Hope for the best, prepare for the worse
06/24GLAXOSMITHKLINE  : Kepler Cheuvreux reiterates its Neutral rating
06/24GLAXOSMITHKLINE  : Price Target From Credit Suisse Raised to GBP14 From GBP13 Bu..
06/24GLAXOSMITHKLINE  : Credit Suisse Boosts GlaxoSmithKline PT, Maintains Underperfo..
06/24GLAXOSMITHKLINE  : Deutsche Bank Lifts GlaxoSmithKline To Sell From Hold, Boosts..
06/24GLAXOSMITHKLINE  : UBS remains Neutral
06/24GLAXOSMITHKLINE  : Credit Suisse remains a Sell rating
06/24ANALYST RECOMMENDATIONS : Beazley, BP, BWX Technologies, Cineworld, Nutanix...
More news
Sales 2021 33 138 M 46 171 M 46 171 M
Net income 2021 3 770 M 5 253 M 5 253 M
Net Debt 2021 21 587 M 30 077 M 30 077 M
P/E ratio 2021 19,1x
Yield 2021 5,67%
Capitalization 70 605 M 98 153 M 98 375 M
EV / Sales 2021 2,78x
EV / Sales 2022 2,61x
Nbr of Employees 94 066
Free-Float 92,3%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 1 411,00 GBX
Average target price 1 518,30 GBX
Spread / Average Target 7,60%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.34%428 269
ROCHE HOLDING AG10.19%321 632
PFIZER, INC.6.09%218 590
NOVARTIS AG1.55%207 926
ABBVIE INC.6.39%201 349